clinical trial · NCT05555550
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
GliomaLow-grade GliomaLow Grade Glioma of BrainGlioma, MalignantGlioma Intracranial18F-Fluciclovine
brief summary
The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG). Imaging with 18F-Fluciclovine PET-MRI will be performed prior to initiation of therapy for LGG, and then 3 months, and 1 year after starting therapy. Changes in 18F-Fluciclovine uptake will be compared to changes in MRI measurements at 3 months and 1 year as compared to baseline.
started
Jul 29, 2026
primary completion
Dec 1, 2026
completion
Sep 1, 2027
last updated
Apr 29, 2026
official title
Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol